BIOGEN INC. (BIIB) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
BIOGEN INC. (Stock Symbol: BIIB) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry. The organization employs approximately 13414 professionals worldwide . The company has established itself as a major market leader with significant institutional backing.
Financial Performance & Key Metrics Analysis
Annual Revenue: $9997 million generating a 16.8% net profit margin .
Market Capitalization: $18125 million - Classified as a large-cap stock with institutional-grade stability.
Return on Equity (ROE): 13.2% - Above-average shareholder return efficiency, indicating areas for operational improvement.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for BIOGEN INC. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
BIOGEN INC. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, positioning itself as a dominant large-cap market leader with significant competitive moats and institutional investor confidence . The company demonstrates robust operational efficiency through strong free cash flow generation of $2773 million annually , complemented by impressive -40.3% year-over-year cash flow growth. The company maintains a healthy 13.3% gross margin, indicating strong pricing power and operational efficiency.